Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Heart Diseases Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

15 recruiting trials for Heart Diseases. Eligibility criteria explained in plain English.

TrialFinderData lists 15 Heart Diseases clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Every phased trial in this set is Phase 3 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.

Research is led by Chinese University of Hong Kong (1), Rush University Medical Center (1), VahatiCor, Inc. (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Specimen Collection (procedure, 1 trial), followed by Ultrasound and Educational Intervention, Educational Intervention Alone.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
15
Total Trials
15
Recruiting Now
1
Phase 3 Trials
10
Sponsors

Track Heart Diseases trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT04706481

Archival of Human Biological Samples in CU-Med Biobank

CU-Med Biobank collaborates with different researchers for collecting and distributing human biospecimens and clinical data for assisting scientific research.

Sponsor: Chinese University of Hong KongEnrolling: 100001 location
RECRUITINGNCT06769880

Use of Bedside Imaging and Community Health Workers for Early Screening and Referral of Pre-symptomatic Stage B Heart...

The goal of this clinical trial is to learn if using point-of-care ultrasound (POCUS) can increase participant engagement and changes in behavior among adults with risk factors...

Sponsor: Rush University Medical CenterEnrolling: 1001 location
RECRUITINGNCT07449325

Self Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)

VahatiCor's Coronary Sinus Reducer (A-FLUX) has been designed to improve angina or angina-like symptoms in patients with CMD. SERRA-I is an early feasibility study that evaluates...

Sponsor: VahatiCor, Inc.Enrolling: 302 locations
RECRUITINGNCT05367297

South Asians and Coronary Plaque Registry

Individuals who self-report as SAs will be recruited to participate in this registry as well as non-SA controls for comparison. All individuals who consent to participate will 1)...

Sponsor: University of Texas Southwestern Medical CenterEnrolling: 3001 location
RECRUITINGNCT06954610

Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation

Background Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting up to 10% of the elderly. Ischemic stroke is the main complication of AF and cardioembolism...

Sponsor: Insel Gruppe AG, University Hospital BernEnrolling: 5001 location
RECRUITINGNCT05452356

Testing VIRTUES Patient Care Sets in Cardiac Patients (VIRTUES Cardiac Care)

Patients with various cardiac conditions (such as those who experience a heart attack) are increasing in Canada and are in need of appropriate cardiac rehabilitation and care....

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sEnrolling: 20001 location
RECRUITINGNCT06455644

Accuracy of LAA Occluder Size Selection: CT vs. DSA During Combined AF Ablation and LAA Occlusion

This study is a prospective, multi-center, randomized controlled trial. The subjects are patients scheduled to undergo a combined procedure of atrial fibrillation (AF) ablation...

Sponsor: First Affiliated Hospital of Shantou University Medical CollegeEnrolling: 2385 locations
RECRUITINGNCT06091475

Therapy to Maintain Remission in Dilated Cardiomyopathy

One third of patients diagnosed with heart failure demonstrate left ventricular reverse remodelling and recovery of cardiac function following a period of medical therapy. The...

Sponsor: Imperial College LondonEnrolling: 501 location
RECRUITINGNCT04950218

Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis

In a prospective cohort study (n = 1.000), the investigators aim to investigate the correlation between cardiac biomarkers and advanced echocardiography and determine whether...

Sponsor: Herlev and Gentofte HospitalEnrolling: 10001 location
RECRUITINGNCT07087184

Gauging Outcomes of Total Milk Ingestion on Lipid and gControl

Atherosclerotic cardiovascular disease remains the leading cause of death for adults in the United States. The cardiovascular impact of milk consumption remains a matter of...

Sponsor: University of California, San FranciscoEnrolling: 1001 location
RECRUITINGNCT06603363

Changes in Plaque Characteristics After Short-term Statin Therapy as Assessed With Coronary CT

INTENSE Trial is a prospective, double-blind, randomized, placebo-controlled, single-center study with two arms (40 mg intensified statin therapy vs matching placebo for...

Sponsor: Prof. Maurovich-Horvat PálEnrolling: 1401 location
RECRUITINGNCT06192251

Complete Lifestyle Medicine Intervention Program

This project will use a mixed design and will be conducted at the West Parry Sound Health Centre. Based on similar studies there is an expected 10% drop-out rate so 20...

Sponsor: Northern Ontario School of MedicineEnrolling: 81 location
RECRUITINGNCT03049254

Mayo AVC Registry and Biobank

Arrhythmogenic ventricular cardiomyopathy (AVC) is a genetic condition which affects the heart and can lead to heart failure and rhythm problems, of which, sudden cardiac arrest...

Sponsor: Mayo ClinicEnrolling: 10002 locations
RECRUITINGNCT01280825

The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

The purpose of this study is to collect DNA samples from patients undergoing routine care at the University of Chicago. These samples will be tested for differences in genes that...

Sponsor: University of ChicagoEnrolling: 12001 location
RECRUITINGPhase 3NCT06563895

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a...

Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that...

Sponsor: Eidos Therapeutics, a BridgeBio companyEnrolling: 58720 locations

Frequently Asked Questions

There are currently 15 clinical trials for Heart Diseases, with 15 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Heart Diseases, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Heart Diseases, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.